The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 07, 2014
Filed:
Aug. 17, 2009
Birgit Schoeberl, Cambridge, MA (US);
Brian Harms, Roslindale, MA (US);
Francis David Gibbons, Lexington, MA (US);
Jonathan Basil Fitzgerald, Arlington, MA (US);
Matthew David Onsum, Jamaica Plain, MA (US);
Ulrik Nielsen, Quincy, MA (US);
William Kubasek, Belmont, MA (US);
Birgit Schoeberl, Cambridge, MA (US);
Brian Harms, Roslindale, MA (US);
Francis David Gibbons, Lexington, MA (US);
Jonathan Basil Fitzgerald, Arlington, MA (US);
Matthew David Onsum, Jamaica Plain, MA (US);
Ulrik Nielsen, Quincy, MA (US);
William Kubasek, Belmont, MA (US);
Merrimack Pharmaceuticals, Inc., Cambridge, MA (US);
Abstract
The invention provides methods for treating patients which methods comprise methods for predicting responses of cells, such as tumor cells, to treatment with therapeutic agents. These methods involve measuring, in a sample of the cells, levels of one or more components of a cellular network and then computing a Network Activation State (NAS) or a Network Inhibition State (NIS) for the cells using a computational model of the cellular network. The response of the cells to treatment is then predicted124 based on the NAS or NIS value that has been computed. The invention also comprises predictive methods for cellular responsiveness in which computation of a NAS or NIS value for the cells (e.g., tumor cells) is combined with use of a statistical classification algorithm. Biomarkers for predicting responsiveness to treatment with a therapeutic agent that targets a component within the ErbB signaling pathway are also provided.